Anita D'Souza, MD, discusses an abstract looking at the combination of teclistamab-cqyv, daratumumab, and pomalidomide in 2 ...

Survival in multiple myeloma has improved significantly with the advent of novel, more potent immunotherapies, including CAR ...

A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...

Study of frail older adult patients with myeloma showed reduced disease progression and death with a regimen reducing dexamethasone exposure.

A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...

Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, ...

Tony Newberne is a high-risk myeloma survivor. He is also a CPT, dietary manager, and patient advocate for several nonprofits ...

Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition ...

Bispecific antibodies show strong initial uptake in community settings for multiple myeloma treatment, particularly among ...

The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...

The phase 3 AQUILA study showed a 63.1% progression-free rate at 5 years with daratumumab versus 40.8% with active monitoring ...